scholarly journals Hyaluronic acid degrading enzyme: TMEM2 increase in patients with interstitial cystitis and bladder pain syndrome

2020 ◽  
Vol 19 ◽  
pp. e493-e494
Author(s):  
H. Yamamoto ◽  
T. Yoneyama ◽  
I. Hamano ◽  
Y. Tobisawa ◽  
A. Imai ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Degrading Enzyme

scholarly journals Erratum: Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 39 (5) ◽  
pp. 419
Author(s):  
Xiang Xiao ◽  
Huan Deng ◽  
Mumba Mulutula Chilufya ◽  
Yizhen Lv ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Symptom Index ◽  
Bladder Pain ◽  
Acid Perfusion

Paper link corrected: https://bonoi.org/index.php/si/article/view/636 It has been brought to authors attention that there is a missing part in “Materials and Methods” of the Systematic Review article by Xiao et al., entitled “Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis” in the Volume 39, No. 4 of Science Insights (pp.363-373). The missing part of the “Materials and Methods” is as below: Population: Patients with IC/BPS.Intervention: All patients underwent intravesical HA and/or CS treatment regimen.Comparison: Improvement in symptoms pre-treatment and post-treatment or other treatment regimen.Outcome: The primary outcome was the change in visual analogue scale (VAS) for pain symptom from baseline to the follow-up period; secondary outcomes were the changes in total scores of the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), storage symptoms including frequency and urgency, and bladder capacity.

Changes in Sexual Function of Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome after Intravesical Therapy with a Hyaluronic Acid Solution

2014 ◽  
Vol 11 (9) ◽  
pp. 2256-2263 ◽  
Author(s):  
Man‐Jung Hung ◽  
Tsung‐Hsien Su ◽  
Yi‐Hao Lin ◽  
Wen‐Chu Huang ◽  
Tzu‐Yin Lin ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Acid Solution ◽  
Sexual Function ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Intravesical Therapy ◽  
Bladder Pain

scholarly journals Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 39 (4) ◽  
pp. 361-373
Author(s):  
Xiang Xiao ◽  
Huan Deng ◽  
Mumba Mulutula Chilufya ◽  
Yizhen Lv ◽  
Yan Zhao ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Cochrane Library ◽  
Bladder Pain ◽  
Effect Model ◽  
Significant Difference

Currently, no suitable delivery methods are available for the drugs to interstitial cystitis/ bladder pain syndrome (IC/BPS). Herein we systematically evaluated the therapeutic effects of intravesical infusion of hyaluronic acid (HA) and chondroitin sulfate (CS) in patients with IC/BPS. This study includes randomized controlled trials (RCT) and self-controlled studies of IC/BPS patients treated with HA, CS, or both. English databases like PubMed, Cochrane Library, Embase, and Medline were searched until up to January 31, 2021. Information was extracted based on the inclusion and exclusion criteria, and then meta-analysis was performed. Sixteen studies including 491 patients were included and analyzed. The responsive rate of treatment was 91.24%. In 3 RCTs, the analogue scale (VAS) for pain on fix-effect model was [mean difference, MD -0.57 (95%CI, -1.55, -0.41)]. A significant improvement on random-effect model was [MD -2.78 (95%CI, -3.48, -2.07)] in 13 self-controlled studies. Outcomes on O’Leary-Sant Interstitial Cystitis Symptom Index, Problem Index, frequency, urgency, and bladder capacity were also significantly improved. Subgroup analysis showed significant difference between HA, CS, and the combination, and the perfusion of HA was more effective (Z = 29.97, P < 0.01). Also, different follow-up times after last treatment showed significant difference (Z = 7.69, P < 0.01). It can be beneficial for IC/BPS patients who have not responded to conventional treatments.

scholarly journals Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis

2014 ◽  
Vol 8 (9-10) ◽  
pp. 610 ◽  
Author(s):  
Ömer Gülpınar ◽  
Aytaç Kayış ◽  
Evren Süer ◽  
Mehmet İlker Gökçe ◽  
Adil Güçal Güçlü ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Interstitial Cystitis ◽  
Chondroitin Sulphate ◽  
Sodium Hyaluronate ◽  
Previous Treatment ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Symptom Index ◽  
Bladder Pain ◽  
Significant Difference

Introduction: Patients with a history of bladder pain syndrome/interstitial cystitis (BPS/IC) and who responded poorly or unsatisfactorily with previous treatment were compared taking intravesical hyaluronic acid (HA) or hyaluronic acid-chondroitin sulphate (HA-CS).Methods: Patients were treated with intravesical instillation with 50 mL sterile sodium hyalurinic acid (Hyacyst, Syner-Med, Surrey, UK) (n = 32) and sodium hyaluronate 1.6% sodium chondroitin sulphate 2% (Ialuril, Aspire Pharma, UK) (n = 33). Intravesical instillations were performed weekly in first month, every 15 days in the second month and monthly in third and fourth months, for a total of 8 doses. Patients were evaluated using a visual analog pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), voiding diary for frequency/nocturia, cystometric bladder capacity and voided volume at the beginning and at 6 months. All patients had a potassium sensitivity test (PST) initially. Wilcoxon and Mann-Whitney U tests were used for statistical analysis.Results: In total, 53 patients met the study criteria. There were 30 patients in the HA-CS group (mean age: 48.47) and 23 patients in the HA group (mean age: 49.61) (p > 0.05). The initial PST was positive in 71.7% patients (38/53) overall with no difference between groups (p > 0.05). Responses for VAS, ICCS, ICPS, 24-hour frequency/nocturia statistically improved in both groups at 6 months. There was no significant difference in symptomatic improvement (p > 0.05). Eight patients had mild adverse events.Conclusion: HA and HA/CS instillation can be effective in BPS/IC patients who do not respond to conservative treatment. An important limitation of our study is that the HA dosage of the 2 treatment arms were different. It would be more appropriate with same HA dosage in both groups; however, there was no commercially available glycosaminoglycan (GAG) substance with same HA dosage for single and combination therapy. Large, long-term randomized studies are required to determine if there is a difference between these treatments.

Sign in / Sign up

Export Citation Format

Share Document